10x Genomics, Inc.(TXG)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,099 of 2,960 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
TXG Stock Analysis & AI Quality Score
Data updated 2026-09-12AI stock analysis and institutional research for 10x Genomics, Inc. (TXG), a Technology sector company. 13F Pro's AI-powered ranking engine scores TXG at 40.5/100 on a 32-signal composite quality model, placing it at rank #2,099 of 2,960 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (19.4) and profitability (20.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), 10x Genomics, Inc. reports quarterly revenue of $151.0M, net income of $-17.9M, free cash flow of $15.4M. Top institutional holders of TXG by reported 13-F value include FMR, BlackRock, ARK Investment Management, based on the most recent SEC filings. TXG trades on the Nasdaq exchange and files with the SEC under CIK 1770787. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TXG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for 10x Genomics, Inc. directly from SEC EDGAR. 10x Genomics, Inc.'s 13F Pro composite quality score has ranged between 31 and 49 since 2021, currently 40.5 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$151.0M
Net Income
Q2 2026
$-17.9M
Free Cash Flow
Q2 2026
$15.4M
ROIC
Q2 2026
-9.5%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+5.2% YoYNet Income
+76.2% YoYOperating Income
+68.7% YoYEPS (Diluted)
+77.0% YoYTotal Assets
+13.4% YoYTotal Debt
Op. Cash Flow
+1941.6% YoYFree Cash Flow
+2371.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $642.8M +5.2% | $610.8M -1.3% | $618.7M +19.8% | $516.4M +5.3% | $490.5M +64.1% | $298.8M |
| Net Income | $-43.5M +76.2% | $-182.6M +28.4% | $-255.1M -53.7% | $-166.0M -185.1% | $-58.2M +89.3% | $-542.7M |
| Operating Income | $-61.0M +68.7% | $-194.6M +26.7% | $-265.3M -58.0% | $-167.9M -221.4% | $-52.3M +90.2% | $-534.1M |
| EPS (Diluted) | $-0.35 +77.0% | $-1.52 +30.3% | $-2.18 -49.3% | $-1.46 -175.5% | $-0.53 +90.1% | $-5.37 |
| Total Assets | $1.04B +13.4% | $918.6M -4.8% | $965.1M -6.2% | $1.03B +1.0% | $1.02B +9.6% | $929.3M |
| Total Debt | — | — | — | — | — | $0.00 |
| Operating Cash Flow | $136.1M +1941.6% | $6.7M +143.9% | $-15.2M +54.8% | $-33.6M -57.2% | $-21.4M +90.2% | $-217.9M |
| Free Cash Flow | $130.1M +2371.2% | $-5.7M +91.0% | $-63.8M +61.4% | $-165.3M -34.7% | $-122.7M +51.8% | $-254.6M |
Get alerted when TXG's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for 10x Genomics, Inc. including:
Top Institutional Holders of TXG
FMR LLC
$675.9M17,629,266 shBlackRock, Inc.
$414.2M10,804,070 shARK Investment Management LLC
$383.5M10,003,057 shVANGUARD PORTFOLIO MANAGEMENT LLC
$267.7M6,982,492 shQuantinno Capital Management LP
$209.7M5,469,698 shVANGUARD CAPITAL MANAGEMENT LLC
$194.9M5,082,594 shPRICE T ROWE ASSOCIATES INC /MD/
$174.0M4,539,007 shSumitomo Mitsui Trust Holdings, Inc.
$160.8M4,194,627 shNikko Asset Management Americas, Inc.
$160.7M4,192,517 shMORGAN STANLEY
$128.5M3,351,911 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $675.9M | 17,629,266 |
| BlackRock, Inc. | $414.2M | 10,804,070 |
| ARK Investment Management LLC | $383.5M | 10,003,057 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $267.7M | 6,982,492 |
| Quantinno Capital Management LP | $209.7M | 5,469,698 |
| VANGUARD CAPITAL MANAGEMENT LLC | $194.9M | 5,082,594 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $174.0M | 4,539,007 |
| Sumitomo Mitsui Trust Holdings, Inc. | $160.8M | 4,194,627 |
| Nikko Asset Management Americas, Inc. | $160.7M | 4,192,517 |
| MORGAN STANLEY | $128.5M | 3,351,911 |
Companies Similar to TXG
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
PubMatic, Inc.
Certara, Inc.
COHU INC
Unity Software Inc.
Tenable Holdings, Inc.
LITTELFUSE INC /DE
VARONIS SYSTEMS INC
IMPINJ INC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Technology Companies
View all Technology →Put TXG on your watchlist
Track score changes the day 10x Genomics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TXG a good stock to buy?
13F Pro's AI-powered analysis of 10x Genomics, Inc. (TXG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TXG are available on the TXG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TXG is classified as a mid company.
Which hedge funds own TXG?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TXG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of 10x Genomics, Inc.'s investment landscape.